Table 3

Stratified analysis of the CYP2E1 DraI polymorphism and HNSCC

Sub-grouped studies

Genetic model

No.of Studies

No.Cases/No.Controls

Test of association

Test of heterogeneity


OR (95% CI)

P

Q

P Q

I2


Overall

AT vs. TT

9

2407/2126

1.15(0.90-1.47)

0.25

19.92

0.011

59.84


AA vs. TT

9

2407/2126

1.56(1.06-2.27)

0.021

8.62

0.37

7.21


Dominant

9

2407/2126

1.18(0.94-1.49)

0.13

18.81

0.016

57.47


Asians

AT vs. TT

2

486/561

0.92(0.70-1.19)

0.53

0.13

0.71

0


AA vs. TT

2

486/561

1.99(1.22-3.24)

0.006

0.067

0.79

0


Dominant

2

486/561

1.04(0.81-1.34)

0.72

0.37

0.53

0


Caucasians

AT vs. TT

7

1921/1601

1.24(0.92-1.66)

0.15

14.61

0.02

58.95


AA vs. TT

7

1921/1601

1.08(0.59-1.97)

0.78

6.18

0.40

2.98


Dominant

7

1921/1601

1.22(0.90-1.65)

0.18

16.29

0.01

63.17


High quality

AT vs. TT

7

2189/1663

1.12(0.83-1.51)

0.43

18.33

0.005

67.27


AA vs. TT

7

2189/1663

1.28(0.81-2.03)

0.28

5.89

0.43

0


Dominant

7

2189/1663

1.13(0.85-1.49)

0.38

17.11

0.009

64.93


Low quality

AT vs. TT

2

218/499

1.19(0.82-1.72)

0.35

1.59

0.20

37.10


AA vs. TT

2

218/499

2.36(1.20-4.63)

0.012

0.56

0.45

0


Dominant

2

218/499

1.35(0.95-1.92)

0.085

1.25

0.26

20.00


Tang et al. BMC Cancer 2010 10:575   doi:10.1186/1471-2407-10-575

Open Data